Study compares outcomes for single-port vs multiport partial nephrectomy
"Our research focused on the outcomes at 6 months, [and we] were looking at disease recurrence and hernia occurrence," says Jennifer Nguyen.
Mast cell inhibition therapy found efficacious in chronic pelvic pain syndrome
"About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels," says Praveen Thumbikat, DVM, PhD.
Low-intensity shockwave therapy found to improve erectile dysfunction
"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.
Dr. Arenas-Gallo highlights findings on DNA alteration frequency in Hispanic men with prostate cancer
"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.
Dr. Rodríguez recaps AUA symposium on disparities in urologic research
"We have to be intentional in order to design our trials so that we have a better participation of those groups," says Larissa V. Rodriguez, MD.
Dr. Lutz discusses the expanding role of men’s health clinics in urology
"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.
Dr. Abdallah highlights an AI model with superior predictive accuracy in renal masses
"What we found is that AI+ score using continuous variables had the highest predictive ability of all oncologic outcomes that were measured," says Nour Abdallah, MD.
Dr. Ross on unmet needs with PARP inhibitors in prostate cancer
"A lot to be done in terms of moving PARP inhibitors earlier. Is that safe? Where do we get the most bang for our buck? And does the therapy have to be indefinite?" says Ashley E. Ross, MD, PhD.
Dr. Chughtai highlights recent advances in diagnostics for male LUTS
"When it comes to BPH therapy, we've seen a lot of innovation when it comes to the therapeutics; the diagnostics have been a tiny bit behind," says Bilal Chughtai, MD.
Speaking of Urology: 2023 AUA Highlights
Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.
Break Wave Lithotripsy appears safe and efficacious in urolithiasis
"In summary, it was safe and effective. There [were] no serious adverse events...and the vast majority of patients received no anesthesia with very similar results to shock wave lithotripsy,” said Ben H. Chew, MD, MSc, FRCSC.
Dr. Murphy on using race as a factor in developing prostate cancer guidelines
"Because we don't have calibration data on Black, or Hispanic, or Asian men in many of these risk tools, we don't know the impact of these tools as screening tests," says Adam Murphy, MD, MBA, MSCI.
Study assesses prostate cancer prevalence among transgender women
"The most important thing for transgender women and their health care providers to remember is that prostate cancer screening shouldn’t be neglected," said Stephen J. Freedland, MD.
Optilume BPH System shows high efficacy at 12-month follow-up
Treatment with the Optilume BPH System resulted in significant, immediate symptomatic and functional improvements in patients with BPH, according to 12-month data from the PINNACLE study.
Darolutamide in extended duration shows safety and efficacy for nonmetastatic CRPC
“The ARAMIS Rollover Study extended the duration of darolutamide treatment and demonstrated the long-term safety of darolutamide in patients with [nonmetastatic CRPC],” said Neal D. Shore, MD.
Tumor shrinkage, tolerable AEs seen with sintilimab plus axitinib for advanced RCC
“The combination of sintilimab and axitinib had a manageable safety profile and achieved a promising tumor response rate in patient with advanced FH-deficient RCC,” said Xingming Zhang.
Darolutamide linked to lower discontinuation and progression rates in nmCRPC
Data from the retrospective DEAR study linked darolutamide to lower rates of discontinuation and progression to metastatic disease vs enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
Early stent removal following radical cystectomy does not increase risk of UTI, urine leak
"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.
89Zr-DFO-girentuximab imaging shows promise in identifying, stratifying renal tumors
“This is a pivotal phase 3 trial that I think is going to be practice changing to the urology community,” said Brian Shuch, MD.
Dr. Shore highlights EMBARK trial data on enzalutamide in biochemically recurrent prostate cancer
"The hazard ratio was 0.42, which is a 58% reduction of an MFS event in favor of the combination arm," says Neal D. Shore, MD, FACS.
Apalutamide/ADT prolongs PSA PFS in biochemically relapsed prostate cancer
Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.
PRP injections for erectile dysfunction show similar efficacy as placebo
"PRP does not seem to be effective in treating men with erectile dysfunction, at least as a monotherapy,” said Ranjith Ramasamy, MD.
Zenflow Spring System shows promise in BPH
“Zenflow is a novel minimally invasive surgical therapy that delivers a nitinol device into the prostatic urethra displacing the lateral lobes for improved urinary flow,” explained Dean Elterman, MD.
Dr. Kapoor on the development of a platform for genetic testing in prostate cancer
"We found that in the 25-patient pilot study that we did, that the accuracy was about 98% of what a standard sequencer would offer," says Deepak Kapoor, MD.
Pembrolizumab elicits antitumor activity in BCG-unresponsive papillary NMIBC
Beyond demonstrating clinical activity, pembrolizumab was safe and tolerable in this patient population.
Nivolumab continues to improve DFS in MIUC, MIBC after radical surgery
“These results further support nivolumab as a standard of care for high-risk MIUC and MIBC after radical resection,” said Matthew Milowsky, MD.
Novel intravesical chemo delivery system hits high complete response rate in NMIBC
The novel intravesical chemotherapy delivery system TAR-200 elicited complete responses in nearly three-fourths of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.
2023 AUA: Dr. Krambeck recaps the BPH update
The update was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
Novel gene therapy appears safe, reduces episodes in women with OAB, UUI
Single-dose URO-902 appeared to be safe and effective in treating women with overactive bladder and urge urinary incontinence, according to the final analysis of a phase 2a trial.
Dr. Helfand highlights SPOTLIGHT study results on 18F-rhPSMA-7.3 in prostate cancer
"Among the 76 men–who had an average age of about 70 and a PSA value of 4.4–up to 99% of them were able to find recurrent cancers," says Brian Helfand, MD, PhD.
2 Clarke Drive Cranbury, NJ 08512